BFM
NKTR icon

Boothbay Fund Management’s Nektar Therapeutics NKTR Stock Holding History

Boothbay Fund Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,000
Closed -$423K – 2340
2025
Q4 		$423K Buy
+10,000
New +$560K 0.01% 1235
2025
Q3 		– Sell
-20,000
Closed -$517K – 2063
2025
Q2 		$517K Buy
+20,000
New +$225K 0.01% 893
2022
Q1 		– Sell
-12,973
Closed -$2.63M – 2447
2021
Q4 		$2.63M Buy
12,973
+12,213
+1,607% +$2.65M 0.06% 387
2021
Q3 		$205K Buy
+760
New +$183K 0.01% 1572
2020
Q3 		– Sell
-7
Closed -$239K – 1154
2020
Q2 		$239K Buy
+7
New +$2.18K 0.02% 760
2018
Q4 		– Sell
-15
Closed -$1.35M – 808
2018
Q3 		$1.35M Hold
15
– – 0.13% 145
2018
Q2 		$1.08M Buy
+15
New +$17.3K 0.09% 171
2017
Q3 		– Sell
-2,840
Closed -$833K – 723
2017
Q2 		$833K Buy
+2,840
New +$821K 0.17% 130

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Boothbay Fund Management's NKTR Position: Q3 2025 in Review

Boothbay Fund Management sold out of Nektar Therapeutics (NKTR) in Q3 2025, closing a stake of 20,962 shares — an estimated $542K sold.

Boothbay Fund Management first reported a position in NKTR in Q2 2019 and held it in 9 quarters. The position peaked at $788K in Q4 2019. 154 funds tracked by Wall St. Rank hold NKTR as of Q3 2025.

  • Boothbay Fund Management reported no remaining Nektar Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 20,962 Nektar Therapeutics shares in Q3 2025, an estimated $542K.
  • Boothbay Fund Management first reported a position in Nektar Therapeutics in Q2 2019 and held it in 9 quarters.
  • Boothbay Fund Management's Nektar Therapeutics position peaked at $788K in Q4 2019.
  • 154 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2025.

Based on Boothbay Fund Management's 13F filing for Q3 2025, filed 14 Nov 2025.